Thoracic Tumours Register
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
- Кому может быть актуально
- Состояния в реестре: Thoracic Tumors. Базовые параметры: Без ограничений · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Испания
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
Observational, multicenter study in patients with lung cancer and other thoracic tumors. The GECP, in its commitment to improve the treatment and prognosis of patients with lung cancer and other thoracic tumors, has marked the individualization of treatment according to the expression of markers predictive of response to chemotherapeutic agents and molecular inhibitors of cell proliferation as one of its primary objectives. This could significantly improve the prognosis of patients with lung cancer, and will lead to a radical change in routine clinical practice. The aim of the register is to explore all data available of all patients treated because of thoracic tumours.
Подробное описание
Observational, multicenter study in patients with lung cancer and other thoracic tumors. In a prospective and retrospective way, information will be obtained from the clinical history of each patient.
In Europe, patients with lung cancer have a poor prognosis, and there has been only limited improvement between 1999 and 2007. Potential advantages of the centralization of care and the discussion of treatment strategies in multidisciplinary teams, as suggested in other studies,13 require further research. However, the priorities should be to prevent lung cancer by implementing anti-smoking policies and controlling asbestos exposure throughout Europe, such as was recommended by the World Health Organization (WHO) in 2008.14 Other priorities are to reduce levels of residential radon in risk areas, and early diagnosis to improve the results of surgery, which is still the main curative treatment.
The variability in the diagnostic process, treatment and advocacy, as well as the anticipated increase in associated mortality in Spain in coming years, has stimulated the creation of an epidemiological, observational, multicenter study of cases of lung cancer and other thoracic tumors diagnosed and treated by medical personnel, including both thoracic surgeons and medical oncologists. Data from this study will be collected retrospectively and prospectively, so as to enable an extensive study of the epidemiological and therapeutic factors related to the disease.
Первичные конечные точки
- Describe epidemiology characteristics of lung cancer and other thoracic tumors in Spanish people [Срок оценки: up to 10 years]
Критерии участия
Критерии включения
- Patients with thoracic disease, treated with an active treatment or not treated (only palliative care)
Критерии исключения
- Patients with other type of tumours
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Другое
Центры проведения
Испания · 79 центров
- Complejo Hospitalario Universitario de Ferrol — Ferrol
- Complejo Hospitalario Universitario de Albacete — Albacete
- H. Virgen de los Lirios — Alcoy
- Hospital General de Alicante — Alicante
- Hospital de Elche — Elche
- Hospital General de Elda — Elda
- H. Germans Trias i Pujol — Badalona
- Clinica Tres Torres — Barcelona
- … и ещё 71 центр
Публикации
- Provencio M, Cobo M, Rodriguez-Abreu D, Carcereny E, Calvo V, Castro RL, Bernabe R, Bruno MF, Bosch-Barrera J, Barco ED, Medina K, Sanchez-Hernandez A, Suay G, Ortega AL, Vazquez S, Lazaro-Quintela M, Guirado M, Estival A, Blanco M, Cantero A, Massuti B. Biomarker landscape in advanced NSCLC: insights from a national prospective registry. Lung Cancer. 2025 Sep;207:108680. doi: 10.1016/j.lungcan.20 PMID 40749260
- Provencio M, Cobo M, Rodriguez-Abreu D, Carcereny E, Cantero A, Calvo V, Lopez Castro R, Bernabe R, Bosch-Barrera J, Massuti B, Garcia Campelo R, Sanchez-Hernandez A, Laura Ortega A, Guirado M, Del Barco E, Camps C, Casal-Rubio J, Domine M, Angeles Sala M, Padilla A, Luis Gonzalez Larriba J, de Asis Aparisi F; Spanish Lung Cancer Group SLCG/GECP. Describing differences among populations of thoraci PMID 38432027
Идентификаторы
NCT: NCT02941458 · GECP 16/01_RTT